AgingResearch.NewsJoin free

Rsv prefusion f protein-based vaccine

Rsv prefusion f protein-based vaccine has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest story, Nov 12, 2026: “Respiratory syncytial virus vaccine showed similar effectiveness”.

Intervention

1 paper studies it3 findingsUpdated

1 new paper in 30 daysSee all 1 papers on rsv prefusion f protein-based vaccine

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Neurological outcomes were neutral for neurological hospitalizations [VE 14.5% (95% CI, -10.0 to 33.9); NNV=1345]”
Vaccine Effectiveness of RSV Prefusion F Protein-Based Vaccination in Older Adults with Neurological or Cerebrovascular Disease: The DAN-RSV TrialAHA Scientific Sessions 2026 abstract2026doi:10.1161/circ.154.suppl_1.6819

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • 3 of 3 findings with company ties
  • Human trial1

Studies in people

1 study gave rsv prefusion f protein-based vaccine to people and measured what changed.

What changedDesignPeopleSource

down: Decreases hospitalization for RSV-related respiratory tract diseaseVE 100%; 0 vs 1 event; 95% CI not calculable; NNV=1506

no change: Has no effect on neurological hospitalizationVE 14.5% (95% CI -10.0 to 33.9); NNV=1345

down: Lowers the risk of Alzheimer's diseaseVE 57.9% (95% CI -0.8 to 84.1); P=0.041; interaction p=0.04

Randomized trial7,223 people60 years or olderOlder adults; Participants with neurological or cerebrovascular disease; vaccination versus no vaccineAHA Scientific Sessions 2026 abstract, Nov 2, 2026

What did studies of rsv prefusion f protein-based vaccine find?

2

Studies of rsv prefusion f protein-based vaccine measured 2 outcomes: neurological hospitalization and hospitalization for RSV-related respiratory tract disease.

Neurological hospitalization

no changein humans1

1 study

  1. Rsv prefusion f protein-based vaccine showed no clear effect on neurological hospitalization in humans (Vaccination versus no vaccine) (VE 14.5% (95% CI -10.0 to 33.9); NNV=1345).

    “Neurological outcomes were neutral for neurological hospitalizations [VE 14.5% (95% CI, -10.0 to 33.9); NNV=1345]”

    Human trialVaccination versus no vaccine

    Respiratory syncytial virus vaccine showed similar effectiveness

    AHA Scientific Sessions 2026 abstract

Hospitalization for RSV-related respiratory tract disease

downin humans1

1 study

  1. Rsv prefusion f protein-based vaccine decreases hospitalization for RSV-related respiratory tract disease in humans (Participants with neurological or cerebrovascular disease; vaccination versus no vaccine) (VE 100%; 0 vs 1 event; 95% CI not calculable; NNV=1506).

    “VE for RSV-related RTD hospitalization was 100% (0 vs 1 event; 95% CI; not calculable; number needed to vaccinate (NNV)=1506) among participants with neurological/cerebrovascular disease”

    Human trialParticipants with neurological or cerebrovascular disease; vaccination versus no vaccinen = 7,223

    Respiratory syncytial virus vaccine showed similar effectiveness

    AHA Scientific Sessions 2026 abstract

What is rsv prefusion f protein-based vaccine linked with?

1

Studies link rsv prefusion f protein-based vaccine with Alzheimer's disease.

Alzheimer's disease

downin humans1

1 study

  1. Rsv prefusion f protein-based vaccine lowers the risk of Alzheimer's disease in humans (VE 57.9% (95% CI -0.8 to 84.1); P=0.041; interaction p=0.04).

    “with reduced new-onset Alzheimer’s dementia among participants without baseline disease [VE 57.9% (95% CI, -0.8 to 84.1); P=0.041].”

    Human trialParticipants without baseline neurological or cerebrovascular disease; vaccination versus no vaccine

    Respiratory syncytial virus vaccine showed similar effectiveness

    AHA Scientific Sessions 2026 abstract

More on Alzheimer's disease

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
AHA Scientific Sessions 2026 Abstract

Respiratory syncytial virus vaccine showed similar effectiveness

Compared with no vaccination, estimated effectiveness against virus-related respiratory hospitalization was 100% with neurological or cerebrovascular disease (zero versus…Compared with no vaccination, estimated effectiveness against virus-related respiratory hospitalization was 100% with neurological or cerebrovascular disease (zero versus one event) and 82.4% without.

Randomized trialLung
Paper

Related